{"entity":{"id":"angelika-eggert","kind":"person","name":"Angelika Eggert","aka":[],"tldr":"Angelika Eggert is a paediatric oncologist and neuroblastoma researcher.","summary":"Angelika Eggert is Director of the Department of Pediatric Oncology and Hematology at Charité Universitätsmedizin Berlin. A paediatric oncologist, her specialisms are neuroblastoma, paediatric oncology and tumour biology. She studies neuroblastoma biology, including Trk receptor signalling and risk-adapted therapy. Her papers include a Nature Communications study of spatial and temporal intratumour heterogeneity and its consequences for treatment decisions based on a single biopsy, a study showing neuroblastoma cells depend on HDAC11 for mitotic progression, and the randomised GPOH trial NB2004-HR, which tested extended induction chemotherapy in high-risk neuroblastoma. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eggert%20A%5BAuthor%5D%20neuroblastoma"}],"tags":[],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["charite"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department of Pediatric Oncology and Hematology, Charité","institutionId":"charite","specialisms":["Neuroblastoma","Paediatric oncology","Tumour biology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eggert%20A%5BAuthor%5D%20neuroblastoma"}],"papers":[{"title":"Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions","journal":"Nature Communications","year":2021,"doi":"10.1038/s41467-021-26870-z"},{"title":"Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival","journal":"Cell Death & Disease","year":2017,"doi":"10.1038/cddis.2017.49"},{"title":"Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR","journal":"Annals of Oncology","year":2020,"doi":"10.1016/j.annonc.2019.11.011"}],"orcid":"0000-0003-3476-8184"},"route":"/people/angelika-eggert/","neighbours":{"cancer":[{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"}],"institution":[{"id":"charite","kind":"institution","name":"Charité Universitätsmedizin Berlin","route":"/institutions/charite/"}],"idea":[{"id":"idea-bio2-paediatric-first-development","kind":"idea","name":"Develop drugs in children first when the target is a children's target","route":"/ideas/idea-bio2-paediatric-first-development/"}]}}